docetaxel anhydrous has been researched along with inecalcitol in 1 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (inecalcitol) | Trials (inecalcitol) | Recent Studies (post-2010) (inecalcitol) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 23 | 1 | 13 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allyon, J; Deplanque, G; Dufour-Lamartinie, JF; Elaidi, R; Ferrero, JM; Houillier, P; Lerest, C; Mackenzie, S; Maruani, G; Maurina, T; Medioni, J; Oudard, S; Raymond, E; Renaux, S; Rodier, JM | 1 |
1 trial(s) available for docetaxel anhydrous and inecalcitol
| Article | Year |
|---|---|
Phase I safety and pharmacodynamic of inecalcitol, a novel VDR agonist with docetaxel in metastatic castration-resistant prostate cancer patients.
Topics: Aged; Aged, 80 and over; Alkynes; Antineoplastic Combined Chemotherapy Protocols; Cholecalciferol; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Calcitriol; Taxoids; Treatment Outcome | 2014 |